These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1671 related items for PubMed ID: 31959728

  • 1. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer.
    Peng XX, Yu R, Wu X, Wu SY, Pi C, Chen ZH, Zhang XC, Gao CY, Shao YW, Liu L, Wu YL, Zhou Q.
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
    [Abstract] [Full Text] [Related]

  • 2. Serum exosomal microRNAs as predictive markers for EGFR mutations in non-small-cell lung cancer.
    Xia J, Luo M, Dai L, Wang L, Wang L, Zhu J.
    J Clin Lab Anal; 2021 May; 35(5):e23743. PubMed ID: 33682961
    [Abstract] [Full Text] [Related]

  • 3. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
    Shimada Y, Matsubayashi J, Kudo Y, Maehara S, Takeuchi S, Hagiwara M, Kakihana M, Ohira T, Nagao T, Ikeda N.
    Sci Rep; 2021 Apr 09; 11(1):7830. PubMed ID: 33837261
    [Abstract] [Full Text] [Related]

  • 4. Cerebrospinal fluid exosomal microRNAs as biomarkers for diagnosing or monitoring the progression of non-small cell lung cancer with leptomeningeal metastases.
    Li H, Xia M, Zheng S, Lin Y, Yu T, Xie Y, Shen Y, Liu X, Qian X, Yin Z.
    Biotechnol Genet Eng Rev; 2024 Apr 09; 40(1):359-380. PubMed ID: 36852928
    [Abstract] [Full Text] [Related]

  • 5. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
    Chen X, Xu Y, Liao X, Liao R, Zhang L, Niu K, Li T, Li D, Chen Z, Duan Y, Sun J.
    Tumour Biol; 2016 Sep 09; 37(9):11927-11936. PubMed ID: 27075472
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y, Lei Y, Liu L, Zhang S, Wang W, Zhao J, Zhao S, Dong X, Yao M, Wang K, Zhou Q.
    Cancer Med; 2021 Apr 09; 10(7):2216-2231. PubMed ID: 33655698
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
    Liu Q, Yu Z, Yuan S, Xie W, Li C, Hu Z, Xiang Y, Wu N, Wu L, Bai L, Li Y.
    Oncotarget; 2017 Feb 21; 8(8):13048-13058. PubMed ID: 28055956
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement.
    Oya Y, Kuroda H, Nakada T, Takahashi Y, Sakakura N, Hida T.
    Int J Mol Sci; 2020 Apr 09; 21(7):. PubMed ID: 32283823
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients.
    Janpipatkul K, Trachu N, Watcharenwong P, Panvongsa W, Worakitchanon W, Metheetrairut C, Oranratnachai S, Reungwetwattana T, Chairoungdua A.
    Cancer Biomark; 2021 Apr 09; 31(3):281-294. PubMed ID: 33896827
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H, Takeda M, Sakai K, Nakamura Y, Ito A, Hayashi H, Tanaka K, Nishio K, Nakagawa K.
    Lung Cancer; 2019 Jan 09; 127():59-65. PubMed ID: 30642552
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B, Zeng J, Zhang H, Zhu S, Wang H, He J, Yang L, Zhou N, Zu L, Xu X, Song Z, Xu S.
    Front Immunol; 2022 Jan 09; 13():974581. PubMed ID: 36159860
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
    Jin X, Chen Y, Chen H, Fei S, Chen D, Cai X, Liu L, Lin B, Su H, Zhao L, Su M, Pan H, Shen L, Xie D, Xie C.
    Clin Cancer Res; 2017 Sep 01; 23(17):5311-5319. PubMed ID: 28606918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 84.